FOLH1 and prostate cancer: The results of clinical applications of [44Sc]Sc-DOTATOC [3] for the diagnosis of neuroendocrine tumors, as well as [44Sc]Sc-PSMA-617 [9,10] for the diagnosis of prostate cancer have been published.